Clinical trials
Allogeneic Hematopoietic Stem Cell Transplantation Recipient clinical trials
Below are recruiting allogeneic hematopoietic stem cell transplantation recipient clinical trials, each written for real people, not researchers. We’re tracking 62 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06856226Recruiting
Drug metabolism study for stem cell transplant patients
This study looks at how your body processes medications after a stem cell transplant from a donor. It aims to find the best way to test your genes to improve future treatments.
Bethesda, MarylandAges 18–120 - NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT06639854Recruiting
CMV immunity test to guide antiviral prevention after transplant
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Houston, TexasAges 18 years+ - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT06138587RecruitingPhase 1
NK cell therapy after stem cell transplant for high-risk blood cancers
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Boston, MassachusettsAges 18 years+ - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75 - NCT02982902RecruitingEarly Phase 1
T cell treatment for stubborn CMV after stem cell transplant
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
Cleveland, OhioAges 3 months+ - NCT06059391RecruitingPhase 2
Vaccine for stem cell donors to prevent CMV
This trial tests whether giving a CMV vaccine to stem cell donors can help protect recipients from CMV infection after transplant. It is for adults with specific blood cancers who are CMV-positive and have a matched related donor.
Duarte, CaliforniaAges 18–75 - NCT05711667RecruitingPhase 3
Letermovir to prevent CMV after stem cell transplant in kids
This trial tests whether the medicine letermovir can prevent a common virus (CMV) from coming back after an allogeneic stem cell transplant in children. It may help lower the risk of CMV infection during the vulnerable period right after transplant.
Birmingham, AlabamaAges 2–18 - NCT05436418RecruitingPhase 1/Phase 2
Lower-dose transplant medicines to prevent graft-versus-host disease
This early-phase study tests a lower dose of cyclophosphamide given after a stem cell transplant to prevent graft-versus-host disease (GVHD). It also uses sirolimus and mycophenolate to improve how well the donor immune system accepts the transplant, aiming to reduce side effects while keeping protection against GVHD.
Duarte, CaliforniaAges 12–120 - NCT04691622RecruitingPhase 1
Treat chronic norovirus using donor immune cells
This Phase 1 study tests whether giving immune cells made from a donor can help children and adults with long-lasting (chronic) norovirus infection. It’s aimed at people whose immune system is weakened after a stem cell transplant, solid organ transplant, or due to primary immune problems.
Washington D.C., District of ColumbiaAges 3 months–80 years - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04180059RecruitingPhase 1
Anti-DP treatment after stem cell transplant to prevent relapse
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
NantesAges 18–75 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04008368RecruitingPhase 1/Phase 2
Second stem cell transplant for sickle cell with declining donor cells
This Phase 1/2 study tests whether repeating a stem cell transplant can help people with sickle cell disease (SCD) whose donor cells are no longer holding strong. It may help restore healthier blood cell production and reduce symptoms such as pain crises and severe anemia.
Bethesda, MarylandAges 2–80 - NCT03980769RecruitingPhase 2
Stem cell transplant trial for non-cancer blood disorders
This Phase 2 study tests a specific chemotherapy combination (treosulfan, fludarabine, and thiotepa) before an unrelated or matched donor stem cell transplant. It may help people with certain non-cancer blood and immune disorders by trying to reset the immune system using donor stem cells.
Seattle, WashingtonAges Up to 50 years - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT03354728RecruitingPhase 1/Phase 2
Vaccine trial for children with CMV after stem cell transplant
This trial studies a vaccine designed to help the body fight cytomegalovirus (CMV) in children who test positive for CMV and are about to receive a donor stem cell transplant. If it works, it may reduce CMV-related illness during recovery after transplant.
Duarte, CaliforniaAges 1–21 - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT01861106RecruitingPhase 2
Bone marrow transplant for GATA2 mutations
This trial tests a bone marrow transplant (called allogeneic hematopoietic stem cell transplant) as a treatment for people with GATA2 mutations or MonoMAC. The goal is to replace faulty immune cells with healthy donor cells, which may reduce infections and improve immune function.
Bethesda, MarylandAges 6–70 - NCT01852370Enrolling by invitationPhase 1/Phase 2
Lung and bone marrow transplant plan for immune system disorders
This early-phase study tests a step-by-step transplant approach: first replacing the lungs, then doing a bone marrow (stem cell) transplant to treat certain immune deficiency diseases. It may help people whose immune problem has led to severe, end-stage lung disease.
Pittsburgh, PennsylvaniaAges 5–45 - NCT01174108RecruitingPhase 2
Stem cell transplant with donor T-cells for severe bone marrow failure
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
Baltimore, MarylandAges 4–80
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic hematopoietic stem cell transplantation recipient?
- Yes. Clin2 currently lists 62 recruiting allogeneic hematopoietic stem cell transplantation recipient studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic hematopoietic stem cell transplantation recipient trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic hematopoietic stem cell transplantation recipient trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.